Buspirone in depressed outpatients: a controlled study.
One hundred fifty-five outpatients suffering from major depression with significant anxiety entered a double-blind study comparing 8 weeks of treatment with buspirone or placebo. Twenty-nine percent of buspirone and 40 percent of placebo patients discontinued treatment before 8 weeks. Major efficacy measures were the Hamilton Rating Scale for Depression (HAM-D) total score, the HAM-D retardation and anxiety factors, the HAM-D Rickels and Bech core depression clusters, the Clinical Global Impressions (CGI), and the Hopkins Symptom Checklist (HSCL). Results were consistent across all outcome measures, including the two core depression clusters, with treatment response to buspirone significantly better than to placebo at treatment endpoint. Seventy percent of buspirone and 35 percent of placebo patients (p less than .01) were rated moderately or markedly improved after 8 weeks of therapy. Buspirone was found to be safe and well-tolerated by patients with major depression and concomitant anxiety at doses of up to 90 mg/day.
Rickels
K
K
Department of Psychiatry, University of Pennsylvania, Philadelphia.
Amsterdam
J
J
Clary
C
C
Hassman
J
J
London
J
J
Puzzuoli
G
G
Schweizer
E
E
D001008:Anxiety Disorders / Q000150:complications / Q000188:drug therapy*; D002065:Buspirone / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000150:complications / Q000188:drug therapy*; D004311:Double-Blind Method; D006801:Humans; D011569:Psychiatric Status Rating Scales
D002065:Buspirone